KRAUSE’S GROVE, 2 Beach Road, Halfmoon, NY


1:00 PM TO 6:00 PM ~ RAIN OR SHINE

$30.00 per adult ticket at gate - $20.00 for children under 12

includes donation to Harvard Stem Cell Institute.

5 hour picnic with soda, beer, games, raffles, 50/50, live music




Abundant food and dessert being served 1:00 p.m. to 5:00 p.m.

Those who wish to join a pre-picnic motorcycle cavalcade around the beautiful Tomhannock Reservoir in Ali’s honor will meet at the Troy Plaza on Hoosick Street at 10:00 A.M. for sign up and the cavalcade will kick off at 11:00 A.M. sharp.

For more info: https://www.facebook.com/Rally4Ali

For Further Information


For the Run, Wally Urzan


For the Picnic & Cause

Alison Fisk


Thursday, February 24, 2011


Denver, CO -- (SBWIRE) -- 02/23/2011 -- There's nothing quite worse than not being able to see properly. Even worse is a situation where you used to be able to see and then you slowly find your eyesight decreasing, which in turn limits your ability to do the things that you so much enjoyed. One female patient from Ukraine felt exactly that after she was diagnosed with maculodystrophy. Also known as Best's Disease, this patient found that her eyesight was severely affected by the disease process, and by the time she was a young teenager, could no longer read or write.

Our patient spent years trying to find help for her condition and some type of treatment that would help restore if not all of, at least part of, her vision. She was missing out of so much in life and was desperate for help from any direction. Even though she visited handfuls of eye clinics and underwent a number of therapies, her central vision continuously and gradually deteriorated.

At about that time, she was at her wits end, growing despondent and depressed. Then, "My second cousin told me about EmCell clinic, offering absolutely new treatment methods - fetal stem cell treatments."

She didn't understand much about stem cell therapies but she researched the topic, the facility, and their successes in treating dozens of patients with a plethora of issues and problems. Finally, comfortable with her results, she agreed to the treatments. After all, she'd tried other traditional therapies to help improve her vision without success. "I underwent the course of treatment and saw improvements six months later. My central vision not only improved but also stabilized. I'm extremely happy to say I was able to graduate from high school and enter the university, focusing on translation studies."

Now, the 25-year-old female had a chance not only for the present, but also for her future. Ever since the treatments, she's been running full steam ahead, excited to embrace life to its fullest despite her condition.

About Dr. Alexander Smikodub
EmCell is located in Kiev, created by Professor Alexander Smikodub, who holds a Ph.D., and is credited as the inventor of various methodologies of treatment with embryonic stem cells. He's also the head of the Cell Therapy Clinic of National Medical University.

Dr. Smikodub has performed thousands of embryonic stem cell transplants to international patients who arrived every month from foreign destinations such as China, Germany, and the United States (where stem cell therapy treatments have not been approved) to receive treatments that improve quality of life.

The facility focuses on offering stem cell transplantation to help restore function of a variety of organs and tissues, and to prolong life, enhance emotional and mental outlook, and offer effective relief of a variety of conditions and functional disorders.

Finding Renewed Hope
"Presently, I'm living on my own and studying abroad," relates this patient, smiling with happiness. "At the same time, I'm working as a secretary. Even though my eyesight has not restored completely, I'm very happy with the results because the treatments have changed my life dramatically. I'm extremely grateful to the doctors who took care of me and to all the staff at EmCell clinic."

This patient is only one of many that has benefited from the expertise of Dr. Smikodub and his EmCell clinic. "Hundreds of patients travel to facilities around the globe that are making stupendous and exciting advances in stem cell research, technology and treatments," says Pramod Goel, Founder and CEO of PlacidWay, a leading medical resource and provider based in Denver, Colorado.

The gift of sight is not to be taken lightly, and this patient decided that nothing was beyond hope. She was, and continues to be, extremely pleased that she found Dr. Smikodub and has enjoyed the benefits of his expertise and knowledge.

For more information regarding this story or for information regarding EmCell and similar stem cell treatment facilities around the globe, access PlacidWay at PlacidWay.com. Just when you start thinking there's no more hope left, you'll turn a corner and find new options and opportunities that enhance and fulfill your life.

Welcome to Cell Therapy Clinic, EmCell, a private medical center founded in 1994. Our clinic offers advanced patented methods of stem cell treatments for different diseases and conditions.

Thanks for everything, I'm so glad that I spoke to you and found such a Wonderful Stem Cell Therapy Treatment. If you need to visit this hospital then feel free here: 1.303.578.0719, info@placidway.com orhttp://www.placidway.com/profile/768/EmCell-Clinic

Sunday, February 13, 2011

Human Stem Cell Bank At UMASS Medical School Makes Available First Seven Stem Cell Lines

Main Category: Stem Cell Research
Also Included In: Cancer / Oncology;  Diabetes;  Alzheimer's / Dementia
Article Date: 12 Feb 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions   
Current Article Ratings:

Patient / Public:3 stars
3 (2 votes)
Healthcare Prof:not yet rated

The first seven stem cell lines grown and banked at the University of Massachusetts Medical School's Human Stem Cell Bank are ready for worldwide distribution to researchers working on discovering new therapeutic treatments for diseases such as cancer, juvenile diabetes, Alzheimer's and Parkinson's, among others.

Stem cells are different from other cells because they have the ability to not only renew themselves for long periods, but with the right signals, become many different types of cells. Because of these unique properties, scientists are able to use stem cells to learn what makes individual cell types unique, how an organism develops from a single cell to an adult and how healthy cells replace damaged cells in adult organisms.

Developed in partnership with and backed by the Massachusetts Life Sciences Center, the Human Stem Cell Bank provides the biomedical research community with expertly derived and maintained human embryonic stem cell lines for fundamental biological investigation and therapeutic applications. The Bank works with other institutions and researchers to bank and characterize stem cell lines, detailing the cell line and its properties. After the lines are put through rigorous quality control testing by the Bank's experts, they are made available to researchers throughout the country and worldwide.

"This is an important milestone for the Human Stem Cell Bank," said Joseph C. Laning, PhD, senior director of the Human Stem Cell Bank and Registry. "Our goal has always been to provide researchers with the highest quality stem cell lines so they know what they are getting and that the cells they get will perform as described. Having these stem cell lines tested, verified and available frees researchers from the expense and burden of manufacturing cell lines themselves, allowing them instead to focus on their research."

"These are the first stem cell lines in what will be a broad catalog of cell materials we intend to make available to researchers," Laning added.

The seven lines now available at UMass Medical School's Human Stem Cell Bank were developed in the lab of George Daley, MD, PhD, director of the Stem Cell Transplantation Program at Children's Hospital in Boston and provided to the Bank last year. Among the cell lines now available for distribution are five human embryonic stem cell lines (hESC) and two induced pluripotent lines. Induced pluripotent stem cells (iPS) are a type of stem cell derived from other adult cell types such as skin cells. Six additional lines from Dr. Daley's lab have been banked and are scheduled to be made available for distribution later this year.

"We are pleased and excited that access to these seven stem cell lines will be provided to scientists from around the world by Massachusetts - through the UMMS Human Stem Cell Bank," said Susan Windham-Bannister, President & CEO of the Massachusetts Life Sciences Center. "Stem cell research and regenerative medicine are evolving at a rapid pace and represent key areas of innovation in life sciences. The availability of these stem cell lines to the international research community reinforces Massachusetts' role as a global focal point for life sciences research, will advance the current understanding of a host of debilitating diseases, and move us one step closer to discovering new treatments."

In addition to making these seven lines available, the UMMS Human Stem Cell Bank has entered an agreement to bank a catalog of as many as 80 stem cell lines with limited availability (lines 1-17 have been and are still available to the research community) from the Harvard Stem Cell Institute, a scientific collaborative of stem cell scientists at Harvard University and other institutions. "This agreement allows us access to the stem cell lines developed by members of Harvard's Stem Cell Institute for the purposes of banking and distribution," said Laning. "We believe that over time, a majority of these lines will be made available to the research community through the UMMS Human Stem Cell Bank."

Working in conjunction with the Bank, the International Stem Cell Registry offers a searchable, comprehensive online database that includes published and validated unpublished information on human embryonic stem cell lines derived worldwide. Since its inception less than three years ago, the Registry has rapidly expanded and evolved to become the premier source among scientists for stem cell information. To date, more than 10,000 online visitors worldwide have accessed the database.

The Registry includes information on the derivation, availability and characteristics for more than 1,200 hESC and iPS cell lines developed in over 22 different countries, including more than 200 cell lines with genetic disorders. In addition, the curators of the Registry have developed a unique, searchable database of over 1,600 citations that are indexed by cell line name.

An early component of Governor Deval Patrick's 10-year, $1 billion Life Sciences Initiative, the UMMS Human Stem Cell Bank and Registry were established in 2008 in conjunction with the Massachusetts Life Sciences Center. Since then, the Center has committed nearly $9.4 million to the Bank and Registry, helping to position Massachusetts at the forefront of stem cell research. Housed at the Medical School's Shrewsbury campus, it occupies a 15,000-square-foot facility with research and training space.

Jim Fessenden
University of Massachusetts Medical School 

Saturday, February 12, 2011

Hearing With Your Nose? Nasal Stem Cells May Treat Hearing Loss

small text medium text large text
Nose HearingStem cell scientists in Australia may have discovered a new way to treat hearing loss suffered in early childhood. And it's not with a hearing aid or special surgery. In fact, the answer to hearing loss may be right under our nose, quite literally.

The findings, published in the journal STEM CELLS, found that transplanting mucosa-derived stem cells, a form of rapidly renewing tissues in the nose, can help prevent sensorineural hearing loss during its early stages.

Scientists transplanted adult human nasal stem cells into the ears of mice that exhibited signs of hearing loss. The mice were 4 weeks old, the typical age when hearing loss in mice first becomes apparent. Dr. Sharon Oleskevich, lead study author from the Hearing Research Group at The University of New South Wales, said her research team found improvements in hearing function one month later when compared against age-matched mice that received placebo injections.

"It has been demonstrated in a number of studies that stem cells, such as olfactory stem cells, dental pulp stem cells and hair follicle stem cells have the ability to transform into functional cells of the nervous system," Dr. Christian Drapeau, chief science officer of Stemtech International, told AOL Health. "For example, in animal studies, injection of hair follicle stem cells in the spinal cord was able to restore mobility."

He says the olfactory stem cells injected in the cochlear cavity could help reverse or protect sensorineural hearing loss in the same kind of way.

"Examination of hearing levels one month post-surgery demonstrated that hearing thresholds in stem cell-transplanted mice were significantly lower than those of mice that received a placebo injection, indicating that transplanted mice were better able to hear less-intense sounds," Oleskevich told AOL Health in an e-mail.

Doctors and researchers are optimistic their research could impact future treatments of hearing loss.

"As the cochlea is a very sensitive organ, the major challenge to this type of approach is getting a sufficiently large number of cells into the cochlea in a way that does not do further damage," study author Dr. Jeremy M. Sullivan, of Johns Hopkins University, explained to AOL Health. "Another important challenge will also be to determine the mechanisms by which the transplanted cells influence hearing levels."

Sullivan says tracking studies suggest that chemical signaling may be involved and that the transplanted cells may release chemical factors that influence the native cells of the cochlea.

Sensorineural hearing loss occurs when there is a loss of sensory cells in the cochlea, a sensory organ located in the inner ear that enables hearing. This condition can arise during infancy or childhood and is most commonly due to genetic causes.

"Hearing impairments that arise during infancy and childhood can lead to marked deficits in speech and language acquisition, as will as hinder cognitive and psychosocial development," said Oleskevich. She believes the results of this latest study may eventually lead to development of a new treatment for early-onset sensorineural hearing loss.

Drapeau agrees but indicates further study is necessary, particularly with regard to potential complications with the treatment.

Wednesday, February 2, 2011


Scientists are busily filing for legal patents that give them exclusive intellectual property rights. Image: AFP

WASHINGTON — Cures for paralysis, blindness and diabetes could all be in reach with embryonic stem cell research, but the pursuit of medical progress is being choked by the US rush to secure patents, experts say.

Scientists are busily filing for legal patents that give them exclusive intellectual property rights for each discovery they make in the hopes that one day, one will lead to a blockbuster cure and big cash for those who devised it.

But the process means that U.S. scientists -- already stymied by years of government funding freezes linked to controversy over the destruction of human embryos -- often find themselves blocked because other universities or private companies have already secured exclusive rights.

"You just have this complete minefield out there and you know who the victims are? It's the patients," said Bob Lanza, chief scientific officer at Advanced Cell Technology, which is researching the use of human embryonic stem cells to halt some forms of blindness.

Lanza recalls bumping up against his company's main competitor, Geron Corporation, when it came to researching stem cells in reversing diabetes, a process he said he had been working on with animals for many years.

"When I came to ACT to try to do it with stem cells I couldn't because the rights to use embryonic stem cells for diabetes had been exclusively licensed to Geron," he said.

"Here I was, a scientist trying to cure diabetes and I couldn't use my entire lifetime of expertise to try and develop that technology," he said.

Read complete story